ThromboGenics Completes Technology Transfer to Bharat Biotech for Thrombolytic Agent

ThromboGenics NV, a biotechnology company focused on vascular disease, announced the successful completion of the technology transfer to Bharat Biotech International for the manufacture of THR-100, a novel variant of recombinant staphylokinase.

THR-100 is a thrombolytic agent developed for the treatment of acute myocardial infarction and other vascular diseases, based on its ability to dissolve blood clots, ThromboGenics said.

In December 2006, ThromboGenics announced the completion of a license agreement with Bharat Biotech to manufacture, develop and commercialize THR-100 as a replacement for established thrombolytics, such as streptokinase and urokinase, in developing countries. THR-100 has completed Phase II clinical trials in Europe for treatment of AMI, and is expected to enter Phase III in India later this year, according to the company.

Bharat Biotech will use its manufacturing capabilities, along with technological expertise acquired from ThromboGenics, to produce clinical-grade material for upcoming clinical trials, ThromboGenics said.